Drug Database
TR

triamcinolone acetonide (Triesence)

✓ Approved

Novartis AG · NR3C1 · 小分子

什么是 triamcinolone acetonide?

triamcinolone acetonide 是一种小分子,由Novartis AG研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraocular Injection。

药物档案

商品名Triesence
公司Novartis AG
药物类别小分子
分子靶点NR3C1
给药途径Injectable (Others), Intraocular Injection
状态Approved

作用机制

分子靶点

triamcinolone acetonide 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

triamcinolone acetonide 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresAdjuvant therapy✓ Approved
Eye disordersUveitis✓ Approved
Injury, poisoning and procedural complicationsVascular access site inflammation✓ Approved

相关研究文献

PubMedOral diseases2026-11-19

Variation in Basal Serum Cortisol Levels During Treatment of Oral Lichen Planus With 0.5% Triamcinolone Acetonide Mouthrinses: A Prospective Observational Study.

Blanco-Aguilera Elena E, Gándara-Vila Pilar P, Sanmartín-Barragáns Valeria V, Rodríguez-García Javier J et al.

To evaluate changes in basal serum cortisol levels in patients with atrophic-erosive oral lichen planus (OLP) and oral lichenoid lesion (OLL) treated with 0.5% triamcinolone acetonide mouthrinses and to assess the occurrence of clinical manifestations associated with adrenal dysfunction. A prospective observational study was conducted in 68 patients with clinically and histopathologically confirmed atrophic-erosive OLP or OLL. Participants received 0.5% triamcinolone acetonide mouthrinses following a tapering regimen over 3 months. Basal serum cortisol levels were measured at baseline, after 30 days, and after 90 days of treatment. Clinical and demographic variables and treatment-related adverse effects were analyzed. Mean basal serum cortisol levels decreased from 17.05 ± 4.38 μg/dL at baseline to 8.79 ± 7.34 μg/dL after 1 month of treatment. Following dose tapering, serum cortisol levels (SCL) partially recovered to 11.94 ± 6.44 μg/dL at 3 months. No clinical manifestations of adrenal insufficiency were observed. Baseline SCL were significantly associated with serum cortisol concentrations after 1 month (r = 0.34; p < 0.05). Older patients exhibited smaller hormonal fluctuations during treatment. Triamcinolone acetonide induced a transient reduction in SCL without clinically relevant adrenal dysfunction, suggesting a limited systemic impact when administered a tapering regimen.

PMID 43053526
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Evaluation of Intralesional Triamcinolone Acetonide and Platelet-Rich Plasma Therapy in Patients With Mild Patch-Type Alopecia Areata.

Ülker Ramazan R, Özdemir İlknur Yorğun İY, Özkol Hatice Uce HU

Alopecia areata is a long-term autoimmune disease that causes hair loss in approximately 2% of people but does not result in permanent scarring. Intralesional corticosteroid treatment provides effective results; however, long-term use may lead to skin atrophy and telangiectasia. Platelet-rich plasma (PRP), an autologous blood-derived preparation, represents a patient-specific alternative that avoids steroid-related side effects. To compare the efficacy and safety of intralesional PRP and intralesional triamcinolone acetonide (ILTA) in patients with mild patch-type (S1) alopecia areata. This prospective study included patients aged 18-65 years with mild patch-type alopecia areata who were admitted to our clinic between March 2024 and March 2025 and had not received any previous treatment. Patients were allocated into two groups; both groups received a total of three sessions of treatment every 4 weeks. The primary endpoint was the change in SALT score from baseline to the 6th month. Secondary endpoints included the change in SALT score at the 3rd month, clinical response categories, hair pull test conversion, relapse rate during 6-month follow-up, and the adverse-event profile. SALT scores were calculated at baseline, 3 months, and 6 months. Sixty patients (41 males, 19 females; mean age 27.97 ± 7.36 years) completed the study. SALT scores decreased significantly in both groups (p < 0.001). The score decreased from 6.03 to 0.93 in the PRP group and from 6.07 to 1.27 in the ILTA group, with no statistically significant difference between groups (mean difference 0.30; 95% CI -0.77 to 1.37; p = 0.576). The very good response rate (≥ 75% improvement) at six months was 76.67% in the PRP group and 66.67% in the ILTA group. Relapse occurred in 3 of 60 patients (5.0%) during the 6-month follow-up (1/30 (3.33%) in the PRP group and 2/30 (6.67%) in the ILTA group). Both groups experienced only mild adverse events; no serious side effects were observed. In mild untreated patch-type alopecia areata, PRP showed similar efficacy to intralesional triamcinolone acetonide and may be considered an alternative treatment option for mild patch-type alopecia areata.

PMID 43047042
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Efficacy of Laser-Assisted Intralesional Triamcinolone for Pathological Scars: A Systematic Review and Meta-Analysis.

Almutawaa Bader N BN, Almahzoum Kholoud K, Albannai Noof N, Alsuwailem Faisal Fahad FF et al.

Pathological scars result from aberrant wound healing and remain challenging to treat. Intralesional triamcinolone acetonide is the current mainstay of therapy. Recently, adjuvant laser therapy has emerged as a promising strategy to enhance drug penetration and modulate scar vasculature and collagen remodeling. This meta-analysis assesses the clinical efficacy of laser-assisted intralesional triamcinolone in the treatment of pathological scars. In March 2026, we conducted a systematic search of PubMed, Scopus, Web of Science, Embase, and the Cochrane Library for randomized controlled trials (RCTs) and non-randomized studies directly assessing laser plus intralesional triamcinolone. For the meta-analysis, we used R 4.5.0 with R Studio 2024.12.1 + 563. Our review included five RCTs and three non-randomized comparative studies. Six studies encompassing 248 patients were included in the meta-analysis. Compared with intralesional triamcinolone alone, laser combination therapy showed no significant difference in VSS/mVSS reduction (SMD = 0.28, 95% CI: -0.53 to 1.10, p = 0.496), with substantial heterogeneity (I2 = 83.1%). However, when compared with laser monotherapy, the combination significantly improved VSS/mVSS (SMD = -1.16, 95% CI: -1.85 to -0.48, p = 0.0008; I2 = 16.9%). Patient satisfaction appeared higher with combination therapy, but certainty was low, and the comparison with laser monotherapy was based on a single study. For VSS subscales vs. laser alone, combination therapy significantly improved vascularity, pliability, and height, but not pigmentation. Recurrence rates did not differ significantly between groups. Laser plus intralesional triamcinolone may improve scar scores and patient satisfaction compared with laser monotherapy, but current evidence does not demonstrate superiority over intralesional triamcinolone alone. Recurrence benefit remains uncertain. However, our findings are limited by the small number of RCTs and substantial heterogeneity. Future adequately powered RCTs with longer follow-up periods are warranted.

PMID 43047260
阅读全文 →
PubMedJFMS open reports2026-11-18

Use of subconjunctival cyclosporine implants for treatment of feline eosinophilic keratoconjunctivitis: A case report.

Willems Lynn L, Roberts Jordan K JK

A 5-year-old, neutered male domestic shorthair cat was presented for evaluation of chronic bilateral eosinophilic keratoconjunctivitis (EK). The patient had a history of recurrent corneal plaques and conjunctivitis that were initially managed with systemic and topical immunosuppressive therapy. Long-term disease control was limited by poor tolerance of topical ophthalmic medications, resulting in inconsistent treatment and repeated disease recurrence affecting both eyes. Over several years, the cat was treated with subconjunctival triamcinolone acetonide, antiviral therapy, and topical megestrol acetate, with only partial and temporary improvement. As a result of persistent disease and inability to administer long-term topical therapy reliably, bilateral subconjunctival cyclosporine implants were surgically placed. Postoperative management included short-term topical antibiotic therapy. At 10-week and 7-month postoperative examinations, marked clinical improvement was observed, with resolution of most corneal plaques and substantial reduction in conjunctival inflammation. Feline EK is a chronic immune-mediated ocular surface disease that typically requires long-term topical immunosuppressive therapy. Successful management may be limited in patients who are resistant to medication administration. This case demonstrates that subconjunctival cyclosporine implants may represent a viable long-acting treatment option for feline EK when topical therapy cannot be consistently administered. To the authors' knowledge, the use of cyclosporine implants for the management of feline EK has not previously been reported.

PMID 43048052
阅读全文 →
PubMedAnnals of African medicine2026-11-18

Comparative Efficacy of Transforaminal Epidural Platelet-rich Plasma and Triamcinolone in Lumbar Radicular Pain: A Prospective Randomized Controlled Study.

Singh Manish Kumar MK, Kumar Amit A, Singh Sarita S, Singh Garima G et al.

Lumbar radicular pain is a common cause of chronic disability. Transforaminal epidural steroid injections can provide short-term relief, but their use is limited by local and systemic adverse effects. Platelet-rich plasma (PRP), an autologous orthobiologic rich in growth factors, has emerged as a potential alternative because of its regenerative and anti-inflammatory properties. To compare the efficacy, patient satisfaction, and safety of fluoroscopy-guided transforaminal epidural injections of autologous PrecurCell® PRP and triamcinolone in patients with chronic lumbar radicular pain. This prospective randomized controlled study included 60 patients with unilateral lumbar radicular pain of more than 3 months' duration and a baseline Visual Analog Scale (VAS) score of at least 5. Participants were randomized to receive either 4 mL of autologous PrecurCell® PRP or triamcinolone with normal saline through a fluoroscopy-guided transforaminal epidural injection. Pain intensity and patient satisfaction were assessed at baseline and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after the procedure. Both groups showed significant reductions in VAS scores from baseline (P < 0.001). The steroid group achieved maximal pain relief at 1 month, followed by progressive worsening through 6 months. The PRP group showed a later but more sustained improvement, with maximal benefit at 3 months that was maintained through 6 months. Patient satisfaction was significantly higher and more durable in the PRP group (P < 0.001). No major adverse events occurred in either group. Fluoroscopy-guided transforaminal epidural injection of autologous PrecurCell® PRP appears to be a safe and effective alternative to triamcinolone for chronic lumbar radicular pain, with more sustained pain relief and patient satisfaction over 6 months.

PMID 43049191
阅读全文 →
PubMedVestnik otorinolaringologii2026-11-18

[Evaluation of the effectiveness of adjuvant conservative therapy in combination with balloon dilatation in limited larynx and tracheal stenosis].

Kirasirova E A EA, Lafutkina N V NV, Mamedov R F RF, Piminidi O K OK et al.

Localized cicatricial stenosis of the larynx and trachea remains a challenging clinical problem due to the high rate of recurrence following endoscopic interventions. Developing effective adjuvant therapies aimed at preventing restenosis is a pressing task. To evaluate the efficacy of a newly developed adjuvant therapy algorithm combined with surgical treatment for localized laryngeal and tracheal stenosis. The study, conducted between 2023 and 2025 at the Sverzhevsky Research Clinical Institute of Otorhinolaryngology, included 35 patients (9 men, 26 women; mean age 46.3±9.7 years) with localized cicatricial stenosis of the larynx and trachea (post-intubation: 40%; granulomatosis with polyangiitis: 34%; idiopathic: 26%). Patients were divided into two groups. The study group (n=20) underwent balloon dilation combined with the developed adjuvant therapy, which included the intraoperative administration of 1 ml of triamcinolone (40 mg/ml) and a course of bovhyaluronidase azoximer 3000 IU (5 injections at 3-day intervals, starting on the 4th postoperative day, with a repeat course after 14 days). The comparison group (n=15) received only surgical treatment with standard pharmacological support. Efficacy was assessed using the mMRC scale, as well as endoscopic and CT data, at the 12-month follow-up. At baseline, the mean mMRC score was 2.9±0.6 for all patients. One month after treatment, the parameters had improved in both groups (study group: 1.1±0.4; comparison group: 1.2±0.5, p=0.28). At 12 months, dyspnea in the study group had decreased to 0.9±0.3, whereas in the comparison group, the score remained higher at 1.4±0.7 (p=0.02). Airway lumen restoration at 6-12 months was 85±10% in the study group versus 65±15% in the control group (p<0.05). In the comparison group (n=15), two patients required the removal of excess fibrin masses. During the 12-month follow-up, recurrence developed in only one patient (5%) in the study group-a patient with granulomatosis with polyangiitis. In the control group, restenosis of varying severity occurred in four patients (26.6%); three required repeat balloon dilation, and one required the removal of granulation tissue. Tolerability of the adjuvant therapy was satisfactory; no serious adverse events were recorded. The use of adjuvant therapy in the study group resulted in a lower recurrence rate and better functional outcomes. The developed combined treatment algorithm, which combines balloon dilation with adjuvant therapy using triamcinolone and bovhyaluronidase azoximer, has demonstrated high clinical efficacy and safety in the treatment of limited laryngeal and tracheal stenosis.

PMID 43046747
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多triamcinolone acetonide